Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2019

View Archived Issues

Gorilla virus makes stealth vaccine vector

Results from first clinical study evaluating KB-195 in patients with urea cycle disorders

Akouos reveals lead program for sensorineural hearing loss

Armata developing AP-PA02 targeting P. aeruginosa to treat respiratory infections

A silica cage ensures thermal stability of tuberculosis vaccine candidates without refrigeration

Eisai and Biogen decide to discontinue phase III MISSION AD program of elenbecestat

Recruitment ongoing in phase I study of DFP-14927

Replimune and Regeneron initiate phase II study of cemiplimab in cutaneous squamous cell carcinoma

Mutations in the PTCD3 gene identified as a novel cause of Leigh syndrome

Design of novel zebrafish models of cystinosis

Siponimod shows efficacy in combined toxic and inflammatory animal model of multiple sclerosis

NTP-42 alone and combined with sildenafil alleviates experimental pulmonary arterial hypertension

New biomarkers for NSCLC identified

Interrupting obesity-associated breast cancer progression

Incyte divulges new MAP4K1 inhibitors

New genes linked to mitral valve prolapse

Ono Pharmaceutical patents lysophospholipid S1P5 receptor agonists

ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors

Universita di Pisa identifies SIRT1 activators

FDA clears initiation of phase I trial of oral foralumab

Southern Research Institute discovers NF-kappaB activators

FDA and EMA offer Auris Medical guidance on phase II/III trial with Keyzilen

Phase III CANDOR study of daratumumab in multiple myeloma meets primary endpoint

Oncotartis conducts first-in-human study of OT-82 in relapsed or refractory lymphoma

Bayer launches first-in-human study of BAY-2416964 in advanced cancer

Model of sleep-disordered breathing may clarify associated disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...